Binding of imipramine to phospholipid bilayers using radioligand binding assay

Area of Science:

• Pharmacology
• Biochemistry
• Membrane Biophysics

Background:

• Tricyclic antidepressants (TCAs) are widely used for treating depression.
• The precise mechanism of TCA action, particularly their interaction with biological membranes, remains incompletely understood.
• Phospholipids, major components of cell membranes, can influence drug binding and efficacy.

Purpose of the Study:

• To investigate the binding characteristics of imipramine (IMI) to neutral and negatively charged model lipid membranes.
• To elucidate the role of electrostatic interactions and membrane composition in imipramine binding.
• To explore the implications of these findings for the mechanism of antidepressant action.

Main Methods:

• Radioligand binding assays were employed to quantify imipramine binding.
• Lipid bilayers composed of phosphatidylcholine (neutral) and phosphatidylserine (negatively charged) were utilized.
• Centrifugation and filtration techniques were used to separate bound and unbound drug.
• Gouy-Chapman theory was applied to correct for electrostatic effects.

Main Results:

• Imipramine exhibited augmented binding to negatively charged phosphatidylserine membranes compared to neutral phosphatidylcholine membranes due to electrostatic attraction.
• Binding isotherms, after correction for electrostatic effects, were characterized by surface partition coefficients and binding parameters (association constants, binding capacities).
• Imipramine binding to model membranes was confirmed to be heterogeneous, involving both surface adsorption and incorporation into the hydrophobic core.

Conclusions:

• Negatively charged phospholipids significantly influence and enhance the binding of imipramine to lipid membranes.
• The heterogeneous binding suggests complex interactions between imipramine and the lipid bilayer.
• These findings support the hypothesis that the lipid composition of biological membranes plays a crucial role in the therapeutic mechanism of antidepressants like imipramine.